Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (1-10 of 364) with videos related to

Pageof 37
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 27, 2019
ReplyBenjamin Pariente, Edouard Louis
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic ReviewBenjamin Pariente, Shurong Hu, Dominik Bettenworth, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience. Author's replyBenjamin Pariente
Current Opinion in Gastroenterology|June 4, 2015
When it is not inflammatory bowel disease: differential diagnosisEdouard Louis
Inflammatory Intestinal Diseases|February 28, 2022
Stopping Anti-TNF in Crohn's Disease Remitters: Pros and Cons: The ProsEdouard Louis
Frontiers in Medicine|January 24, 2020
Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel DiseaseEdouard Louis
Inflammatory Bowel Diseases|March 17, 2018
Stopping Biologics in IBD-What Is the Evidence?Edouard Louis
Digestive Diseases (Basel, Switzerland)|September 14, 2013
Strategic use of immunosuppressants and anti-TNF in inflammatory bowel diseaseEdouard Louis
Journal of Crohn'S & Colitis|November 3, 2018
Do We Still Need Predictors of Disease Severity When Applying a Treat-to-Target Approach in Inflammatory Bowel Disease?Edouard Louis
Digestive Diseases (Basel, Switzerland)|July 17, 2012
Epidemiology of the transition from early to late Crohn's diseaseEdouard Louis
Pageof 37

Showing results (1-10 of 364) with videos related to

Sort By:
Pageof 37
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 27, 2019
ReplyBenjamin Pariente, Edouard Louis
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic ReviewBenjamin Pariente, Shurong Hu, Dominik Bettenworth, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience. Author's replyBenjamin Pariente
Current Opinion in Gastroenterology|June 4, 2015
When it is not inflammatory bowel disease: differential diagnosisEdouard Louis
Inflammatory Intestinal Diseases|February 28, 2022
Stopping Anti-TNF in Crohn's Disease Remitters: Pros and Cons: The ProsEdouard Louis
Frontiers in Medicine|January 24, 2020
Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel DiseaseEdouard Louis
Inflammatory Bowel Diseases|March 17, 2018
Stopping Biologics in IBD-What Is the Evidence?Edouard Louis
Digestive Diseases (Basel, Switzerland)|September 14, 2013
Strategic use of immunosuppressants and anti-TNF in inflammatory bowel diseaseEdouard Louis
Journal of Crohn'S & Colitis|November 3, 2018
Do We Still Need Predictors of Disease Severity When Applying a Treat-to-Target Approach in Inflammatory Bowel Disease?Edouard Louis
Digestive Diseases (Basel, Switzerland)|July 17, 2012
Epidemiology of the transition from early to late Crohn's diseaseEdouard Louis
Pageof 37